Sign in

    Matt Keeler

    MedTech Analyst at Credit Suisse

    Matt Keeler is a MedTech Analyst at Credit Suisse, specializing in healthcare sector research with a focus on medical technology and biotechnology firms. He has covered companies including Endologix and Leap Therapeutics, contributing industry insights at major conferences such as the Credit Suisse Annual Healthcare Conference and actively participating in earnings calls. Having started his analyst career at Credit Suisse, Keeler is recognized for his thorough research and commercial diligence in the MedTech industry, with engagement notable for insightful inquiries into clinical and commercial milestones. He holds professional credentials verified by FINRA, including securities licenses reflecting his compliance with industry standards.

    Matt Keeler's questions to MCUR leadership

    Matt Keeler's questions to MCUR leadership • Q2 2015

    Question

    Matt Keeler from Credit Suisse inquired about the company's commercial expectations, including the timeline to achieve full commercial coverage, and asked how CureXcell's clinical data would resonate with physicians compared to competitors' claims from smaller studies.

    Answer

    President & CEO Nissim Mashiach outlined a commercial launch timeline for early 2018, following a BLA filing in H2 2016 and a 10-month FDA review. CFO Mark Page noted that dialogue with CMS would begin in 2016. CMO Mike Molyneaux emphasized that their reimbursement cycle would be faster than typical MedTech products due to rigorous FDA-approved trial data. Regarding competition, Dr. Molyneaux stated that physicians view their rigorous Phase III trial as the 'next great hope' and understand its superiority over smaller, non-blinded studies. Mr. Mashiach highlighted CureXcell's ease of use as a key differentiator.

    Ask Fintool Equity Research AI